company background image

Theradiag ENXTPA:ALTER Stock Report

Last Price


Market Cap







02 Oct, 2022


Company Financials +
ALTER fundamental analysis
Snowflake Score
Future Growth3/6
Past Performance0/6
Financial Health3/6

ALTER Stock Overview

Theradiag SA develops, manufactures, and markets in-vitro diagnostic products.

Theradiag Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theradiag
Historical stock prices
Current Share Price€2.30
52 Week High€2.75
52 Week Low€1.31
1 Month Change51.12%
3 Month Change39.39%
1 Year Change21.05%
3 Year Change124.39%
5 Year Change-8.00%
Change since IPO-59.36%

Recent News & Updates

Shareholder Returns

ALTERFR Medical EquipmentFR Market

Return vs Industry: ALTER exceeded the French Medical Equipment industry which returned -20.1% over the past year.

Return vs Market: ALTER exceeded the French Market which returned -12.3% over the past year.

Price Volatility

Is ALTER's price volatile compared to industry and market?
ALTER volatility
ALTER Average Weekly Movement17.4%
Medical Equipment Industry Average Movement6.4%
Market Average Movement4.9%
10% most volatile stocks in FR Market9.3%
10% least volatile stocks in FR Market2.8%

Stable Share Price: ALTER is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: ALTER's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

198660Bertrand De Castelnau

Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis.

Theradiag Fundamentals Summary

How do Theradiag's earnings and revenue compare to its market cap?
ALTER fundamental statistics
Market Cap€29.93m
Earnings (TTM)-€731.69k
Revenue (TTM)€12.78m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALTER income statement (TTM)
Cost of Revenue€7.91m
Gross Profit€4.87m
Other Expenses€5.60m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.056
Gross Margin38.11%
Net Profit Margin-5.72%
Debt/Equity Ratio21.8%

How did ALTER perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ALTER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALTER?

Other financial metrics that can be useful for relative valuation.

ALTER key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-106.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ALTER's PS Ratio compare to its peers?

ALTER PS Ratio vs Peers
The above table shows the PS ratio for ALTER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.9x
MKEA Mauna Kea Technologies
ALDMS Diagnostic Medical Systems
ALIKO Ikonisys
ALTER Theradiag

Price-To-Sales vs Peers: ALTER is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (12.9x).

Price to Earnings Ratio vs Industry

How does ALTER's PE Ratio compare vs other companies in the FR Medical Equipment Industry?

Price-To-Sales vs Industry: ALTER is good value based on its Price-To-Sales Ratio (2.3x) compared to the French Medical Equipment industry average (2.6x)

Price to Sales Ratio vs Fair Ratio

What is ALTER's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALTER PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: ALTER is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Share Price vs Fair Value

What is the Fair Price of ALTER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALTER's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALTER's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Theradiag forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score


Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALTER is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: ALTER is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALTER is expected to become profitable in the next 3 years.

Revenue vs Market: ALTER's revenue (5.2% per year) is forecast to grow slower than the French market (5.3% per year).

High Growth Revenue: ALTER's revenue (5.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALTER's Return on Equity is forecast to be low in 3 years time (3.3%).

Discover growth companies

Past Performance

How has Theradiag performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALTER is currently unprofitable.

Growing Profit Margin: ALTER is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALTER is unprofitable, but has reduced losses over the past 5 years at a rate of 56.3% per year.

Accelerating Growth: Unable to compare ALTER's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALTER is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.9%).

Return on Equity

High ROE: ALTER has a negative Return on Equity (-8.24%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Theradiag's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALTER's short term assets (€10.7M) exceed its short term liabilities (€2.4M).

Long Term Liabilities: ALTER's short term assets (€10.7M) exceed its long term liabilities (€3.1M).

Debt to Equity History and Analysis

Debt Level: ALTER has more cash than its total debt.

Reducing Debt: ALTER's debt to equity ratio has increased from 0.9% to 21.8% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALTER has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALTER has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Theradiag current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Theradiag Dividend Yield vs Market
How does Theradiag dividend yield compare to the market?
SegmentDividend Yield
Company (Theradiag)n/a
Market Bottom 25% (FR)2.0%
Market Top 25% (FR)6.1%
Industry Average (Medical Equipment)1.8%
Analyst forecast in 3 Years (Theradiag)n/a

Notable Dividend: Unable to evaluate ALTER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALTER's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALTER's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALTER's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTER has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Bertrand De Castelnau (61 yo)



Mr. Bertrand de Castelnau serves as Chief Executive Officer at Theradiag SA since December 11, 2018 and served as its Director since February 04, 2019 and served as its Managing Director until 2022. He beg...

Board Members

Experienced Board: ALTER's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALTER?
Owner TypeNumber of SharesOwnership Percentage
General Public12,969,09799.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.2%.

Top Shareholders

Top 1 shareholders own 0.34% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Trusteam Finance

Company Information

Theradiag SA's employee growth, exchange listings and data sources

Key Information

  • Name: Theradiag SA
  • Ticker: ALTER
  • Exchange: ENXTPA
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €29.930m
  • Shares outstanding: 13.01m
  • Website:

Number of Employees


  • Theradiag SA
  • 14 rue Ambroise Croizat
  • CS 90136 Croissy Beaubourg
  • Marne-la-Vallée
  • Ile-de-France
  • 77435
  • France


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTERENXTPA (Euronext Paris)YesCommon StockFREURDec 2012
4W6BST (Boerse-Stuttgart)YesCommon StockDEEURDec 2012

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.